Amneal Pharmaceuticals (AMRX) Receivables (2017 - 2026)

Amneal Pharmaceuticals' Receivables history runs 10 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• On a quarterly basis, Receivables fell 99.5% year-over-year to $6.6 million in Q1 2026; TTM through Mar 2026 was $6.6 million, a 99.5% decrease from a year earlier, with the FY2025 full-year figure at $5.7 million, up 16.18% from the prior year.
• Receivables climbed to $6.6 million in Q1 2026 per AMRX's latest filing, from $5.7 million in the prior quarter.
• Across five years, Receivables topped out at $1.5 billion in Q3 2025 and bottomed at $486000.0 in Q4 2022.
• The 5-year median for Receivables is $1.0 billion (2022), against an average of $799.8 million.
• Across the five-year window, Receivables slumped 99.93% in 2022 and soared 126182.3% in 2023, its largest moves.
• Year by year, Receivables stood at $486000.0 in 2022, then surged by 126182.3% to $613.7 million in 2023, then plunged by 99.2% to $4.9 million in 2024, then increased by 16.18% to $5.7 million in 2025, then rose by 15.24% to $6.6 million in 2026.
• Per Business Quant, the three latest AMRX Receivables figures stand at $6.6 million (Q1 2026), $5.7 million (Q4 2025), and $1.5 billion (Q3 2025).